Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


APHINITY Combo Details Contain No Surprise, Puma's Nerlynx May Benefit

Executive Summary

Details of Roche's early stage breast cancer study APHINITYs were positive as previously headlined, but it's likely to confine use of Perjeta, Herceptin and chemotherapy to higher-risk, node-positive patients.

You may also be interested in...

Roche Digs In To Early Breast Cancer With New Perjeta Approvals

Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.

Roche Lifts Outlook, Spotlights Perjeta To Drive Growth

A “phenomenal” start by Ocrevus and the use of two other newly launched medicines, Tecentriq and Alecensa, drove sales growth at Roche in the first half of 2017 – with the previously cautious company now upgrading its financial outlook for the year and expecting further growth from breast cancer therapy Perjeta.

Roche Pushes The Boundaries Of Cancer Immunotherapy

Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts